(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
7 November 2013 (07.11.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/164754 A2

(51) International Patent Classification:
A61K 39/00 (2006.01)

(21) International Application Number:
PCT/IB2013/053377

(22) International Filing Date:
29 April 2013 (29.04.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/642,844 4 May 2012 (04.05.2012) US

(71) Applicant: **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, New York 10017 (US).

(72) Inventors: **BINDER, Joseph John**; 12282 Cornwallis Square, San Diego, California 92128 (US). **CHO, Helen Kim**; 4127 Twilight Ridge, San Diego, California 92130 (US). **DERMYER, Michael Robert**; 6450 Terraza Portico, Carlsbad, California 92009 (US). **JOOSS, Karin Ute**; 3712 Garden Lane, San Diego, California 92106 (US). **PIERCE, Brian Gregory**; 62 Moore Road, Wayland, Massachusetts 01778 (US). **TAN, Joyce Tsi**; 112 Shadow Ridge Place, Chapel Hill, North Carolina 27516 (US). **TSAI, Van To**; 12892 Ralston Circle, San Diego, California 92130 (US).

(74) Agents: **KLEIMAN, Gabriel L.** et al.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i))*

[Continued on next page]

(54) Title: PROSTATE-ASSOCIATED ANTIGENS AND VACCINE-BASED IMMUNOTHERAPY REGIMENS

FIG. 37



(57) Abstract: The present disclosure provides (a) isolated immunogenic PAA polypeptides; (b) isolated nucleic acid molecules encoding immunogenic PAA polypeptides; (c) vaccine compositions comprising an immunogenic PAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic PAA polypeptide; (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions; and (e) vaccine-based immunotherapy regimens which involve co-administration of a vaccine in combination with an immune-suppressive-cell inhibitor and an immune-effector-cell enhancer.

WO 2013/164754 A2

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*